'Insignificant' prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy
- PMID: 17387320
- DOI: 10.1038/sj.pcan.4500963
'Insignificant' prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy
Abstract
'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. From our review, minimal disease on biopsy does not reliably predict minimal disease in the subsequent prostatectomy specimen, in terms of the size and grade of tumor, extracapsular extension or positive margins. Thus, reasoned accounting should be made of other data before undertaking a course of radiation therapy as monotherapy, particularly prostate-specific antigen kinetics and potential molecular markers.
Similar articles
-
After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.BJU Int. 2008 Jan;101(2):170-4. doi: 10.1111/j.1464-410X.2007.07270.x. BJU Int. 2008. PMID: 18173824
-
'Insignificant' prostate cancer on prostatectomy and cystoprostatectomy: variation on a theme 'low-volume/low-grade' prostate cancer?BJU Int. 2010 Aug;106(3):304-15. doi: 10.1111/j.1464-410X.2010.09499.x. BJU Int. 2010. PMID: 20653654 Review.
-
PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17. J Urol. 2008. PMID: 18801539
-
Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.J Urol. 2007 Nov;178(5):1957-62; discussion 1962. doi: 10.1016/j.juro.2007.07.043. Epub 2007 Sep 17. J Urol. 2007. PMID: 17868719 Clinical Trial.
-
Medical technologies for the diagnosis of prostate cancer.Expert Rev Med Devices. 2007 Mar;4(2):227-39. doi: 10.1586/17434440.4.2.227. Expert Rev Med Devices. 2007. PMID: 17359227 Review.
Cited by
-
Pathologic basis of focal therapy for early-stage prostate cancer.Nat Rev Urol. 2009 Apr;6(4):205-15. doi: 10.1038/nrurol.2009.29. Nat Rev Urol. 2009. PMID: 19352395 Review.
-
The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer.Scand J Urol. 2013 Oct;47(5):347-55. doi: 10.3109/21681805.2013.813962. Epub 2013 Jul 24. Scand J Urol. 2013. PMID: 23883427 Free PMC article. Review.
-
Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer.Nutr Cancer. 2010;62(8):1036-43. doi: 10.1080/01635581.2010.492085. Nutr Cancer. 2010. PMID: 21058191 Free PMC article. Clinical Trial.
-
Schema and cancer detection rates for transperineal prostate biopsy templates: a review.Ther Adv Urol. 2022 Jun 26;14:17562872221105019. doi: 10.1177/17562872221105019. eCollection 2022 Jan-Dec. Ther Adv Urol. 2022. PMID: 35783921 Free PMC article. Review.
-
Sampling the spatial patterns of cancer: optimized biopsy procedures for estimating prostate cancer volume and Gleason Score.Med Image Anal. 2009 Aug;13(4):609-20. doi: 10.1016/j.media.2009.05.002. Epub 2009 May 23. Med Image Anal. 2009. PMID: 19524478 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical